Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors

Abstract Objectives/Hypothesis The extra domain B (ED‐B) of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is expressed in the majority of aggressive solid human tumors, whereas it is not detectable in normal vessels and tissues. Study Design In view of the diagnostic and therapeutic clinical applications of the L19 antibody, which is specific for the ED‐B domain of fibronectin, a prospective immunohistochemical analysis of different head and neck tumors was performed. Methods In all, 82 head and neck tissue biopsy specimens were immunohistochemically analyzed using the L19 antibody. They consisted of 53 different malignant tumors, 8 benign tumors, 10 nontumoral lesions, and 11 normal control tissues. Results A strong positive staining with the L19 antibody could be observed in 87% of the investigated malignant tumors, in only 38% of the benign tumors, and in 20% of the nontumoral lesions ( P <.0001). The extra domain B was completely absent in the normal control tissue samples. Conclusions The results show that ED‐B is abundantly expressed around the neovasculature and in the stroma of the majority of malignant tumors of the head and neck but is undetectable in normal tissues. The ED‐B domain of fibronectin is a good‐quality tumor‐stroma–associated antigen that warrants clinical trials with antibody‐based pharmaceuticals, including immunoscintigraphic investigations and radioimmunoguided surgery with the radiolabeled L19 antibody.